This site requires JavaScript to render the code.

Need to know how to enable JavaScript? Go here.

On 13 February 2018 the United States patent and Trademark Office granted US patent 9,891,432 B2 to Self-screen B.V. The invention relates to the method for detecting HPV-induced high-grade precancerous lesions and HPV-induced invasive cancers. The method comprises the detection of hypermethylation in the PRDM14 and/or FAM19A4 gene in a cell whereby such methylation indicates the presence of precursor lesions or invasive cancers. The precursor lesions being characterized by having a cancerous like methylation pattern. The invention also comprises the use of the two markers in a test kit and enables Self-screen to develop and market such a kit. The FAM19A4 marker is currently being used in the QIAsure Methylation test, this is a real-time PCR-based molecular assay to distinguish women with cervical (pre)cancer. The test can be used as triage test for women with a positive HPV DNA test or for women with ASC-US cytology to identify those women that need to be referred for a colposcopy and is being marketed and distributed by Qiagen. Investigation to use the markers in other sample types than cervical scrapes, like urine, is ongoing and will possibly lead to a new diagnostic assay that is compatible with easily available sample material.